All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.
Ublituximab + umbralisib granted FDA fast track designation for the treatment of CLL
By Claire Baker
Bookmark this article
Ublituximab in combination with umbralisib (U2) has been granted fast track designation by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with chronic lymphocytic leukemia (CLL).
The decision follows positive data from the phase III UNITY-CLL trial comparing U2 to obinutuzumab + chlorambucil in patients with treatment-naïve and relapsed and/or refractory (R/R) chronic CLL, which met its primary endpoint in May 2020.
U2
The U2 combination regimen comprises the investigational, anti-CD20 monoclonal antibody, ublituximab, and the investigational, once-daily, oral inhibitor of PI3K-delta and CK1-epsilon, umbralisib.
GlobeNewswire. TG Therapeutics announces fast track designation granted by the FDA to ublituximab in combination with umbralisib for the treatment of adult patients with chronic lymphocytic leukemia. https://www.globenewswire.com/news-release/2020/10/21/2111770/0/en/TG-Therapeutics-Announces-Fast-Track-Designation-Granted-by-the-FDA-to-Ublituximab-in-Combination-with-Umbralisib-for-the-Treatment-of-Adult-Patients-with-Chronic-Lymphocytic-Leuke.html. Published Oct 21, 2020. Accessed Nov 12, 2020.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youYour opinion matters
60 votes - 48 days left ...
Related articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox